News | EP Lab | May 06, 2021

Case Report on CRT Lead Placement in Obstructed Veins Using Surfacer System

The Bluegrass Vascular Surfacer System is designed to reliably, efficiently and repeatedly gain central venous access by inserting the Surfacer System through the right femoral vein and navigating it up through the patient’s venous system with an exit point in the right internal jugular vein, the optimal location for placing a central venous catheter. 

The Surfacer System is designed to reliably, efficiently and repeatedly gain central venous access by inserting the Surfacer System through the right femoral vein and navigating it up through the patient’s venous system with an exit point in the right internal jugular vein, the optimal location for placing a central venous catheter. 


May 6, 2021 - Bluegrass Vascular Technologies announced the publication of a report documenting the clinical utility of the its Surfacer System to gain venous access prior to the placement of cardiac resynchronization therapy (CRT) device leads in a patient with obstructed central veins. 

The paper, published in Clinical Case Reports,[1] adds to the body of evidence which supports the use of the Surfacer System to gain vascular access in patients who require venous access but have occlusions and damaged vessels which preclude the ability to access the central vasculature for electrophysiology (EP) device lead placements.

For the present paper, the Surfacer System was utilized to gain central venous access which facilitated placement of three cardiac leads prior to the placement of an implantable CRT defibrillator in a patient with bilateral occluded brachiocephalic veins and an occluded superior vena cava. The procedure was performed with Professor Aldo Rinaldi, a Consultant Cardiologist at Guy's and St Thomas' Hospital in London. The patient had an extensive history of central venous stenosis and occlusions associated with the placement of previous CRT devices with a history of facial swelling and bilateral arm edema resulting from the above. Prior the procedure described in the paper, the patient was implanted with a leadless pacemaker system due to unsuccessful attempts to gain central venous access using a recanalization procedure. 

“The development of central venous occlusions is common in patients with permanent transvenous pacing leads and can become challenging when the need arises to replace these leads or a CRT device, “stated the paper's co-author Stephen Black, M.D., professor of venous surgery at King's College London and Consultant Vascular Surgeon at Guy’s and St Thomas’ Hospital in London, U.K. “The Surfacer System enabled us the ability to access the central venous system and then safely place standard transvenous leads and position a cardiac defibrillator in the preferred upper chest location for a patient who had extensive venous occlusions and failed a previous attempt to obtain central venous access.” 

“The present case adds to the clinical evidence supporting the use of the Surfacer System as an option for patients who require central venous access but suffer from occlusions of the vasculature which prevent the use of these vessels,” stated Gabriele Niederauer, Ph.D., CEO and President of Bluegrass Vascular. “The ability to utilize the Surfacer System to obtain central venous access in patients with occluded vessels permits a safe and efficient approach to addressing an important, and often lifesaving, clinical need for these patients. The use of the Surfacer System to gain central venous access and enable the placement of transvenous cardiac leads combined with the demonstrated adoption of our technology for use in patients requiring central venous catheters for hemodialysis and other therapies represent extremely large market opportunities for the use of our device.” 

The Surfacer System is designed to reliably, efficiently and repeatedly gain central venous access by inserting the Surfacer System through the right femoral vein and navigating it up through the patient’s venous system with an exit point in the right internal jugular vein, the optimal location for placing a central venous catheter. 

This proprietary Inside-Out approach allows for the placement and maturation of permanent arteriovenous access options that are associated with improved patient outcomes and reduced cost of care for both hospitals and hemodialysis providers. The Surfacer System has received FDA De Novo device clearance in the U.S. and is CE marked in Europe. The device is currently distributed in North America and Europe by Merit Medical, a global manufacturer and distributor of medical devices. 

Bluegrass Vascular Technologies is a medical technology company dedicated to developing and commercializing lifesaving devices and methods that address shortcomings in vascular access procedures. 

For more information www.bluegrassvascular.com

Find more EP lab technology news

Reference:

1. Johanna B. Tonko, Stephen A. Black, Christopher A. Rinaldi. “Inside‐Out” Central Venous Access approach with infraclavicular exit for right‐sided CRT‐D Implantation in bilateral brachiocephalic and superior vena cava occlusion. Clinical Case Reports. First published 4 April, 2021. https://doi.org/10.1002/ccr3.3980.

 

Related Content

News | Cardiac Resynchronization Therapy Devices (CRT)

October 27, 2021 ​​— EBR Systems Inc., developer of the world’s first wireless cardiac pacing system for heart failure ...

Home October 27, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

August 3, 2021 — In association with Heart Rhythm 2021, Biotronik announced first enrollments in the landmark BIO ...

Home August 03, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

March 3, 2021 — Medtronic announced new results from the landmark REVERSE trial, evaluating outcomes of cardiac ...

Home March 03, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

May 13, 2020 — Cardiac resynchronization therapy (CRT) using biventricular pacing (BVP) or His bundle pacing (HBP) is ...

Home May 13, 2020
Home
Feature | Cardiac Resynchronization Therapy Devices (CRT) | Valentina Kutyifa M.D., Ph.D.

Cardiovascular disease is the leading cause of death for women in North America, and women with heart failure often ...

Home March 09, 2020
Home
News | Cardiac Resynchronization Therapy Devices (CRT) | Dave Fornell, Editor

May 15, 2019 — A pilot trial has shown His pacing in cardiac resynchronization therapy (CRT) has been shown to ...

Home May 15, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

April 29, 2019 — Biotronik announced the full commercial launch of the Acticor device family, including Acticor DX and ...

Home April 29, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

April 18, 2019 – Biotronik announced the European market release of what it calls the world’s smallest implantable ...

Home April 18, 2019
Home
Technology | Cardiac Resynchronization Therapy Devices (CRT)

March 15, 2019 – Biotronik announced U.S. Food and Drug Administration (FDA) approval of the Acticor and Rivacor high ...

Home March 15, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

May 22, 2018 — Medtronic plc announced study results showing its AdaptivCRT algorithm is associated with improved ...

Home May 22, 2018
Home
Subscribe Now